Does Regence Cover Cialis? A Complete 2025 Guide to Tadalafil Insurance Coverage

What Is Cialis (Tadalafil) and What Does the FDA Approve It For?

Cialis is the brand name for tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor manufactured by Eli Lilly. The FDA has approved tadalafil for three distinct indications: erectile dysfunction (ED) at doses of 5 mg, 10 mg, and 20 mg; benign prostatic hyperplasia (BPH) at 5 mg daily; and pulmonary arterial hypertension (PAH) at 40 mg daily under the brand name Adcirca or as generic tadalafil 20 mg twice daily. [1]

The mechanism is straightforward. Tadalafil blocks PDE5, the enzyme that degrades cyclic GMP in smooth muscle. In penile tissue, this sustains vasodilation and allows erection in response to sexual stimulation. In the prostate and bladder neck, the same smooth-muscle relaxation eases urinary flow, which is why the 5 mg daily dose carries an FDA label for BPH. [2]

Generic tadalafil became available in the United States in September 2018 after Eli Lilly's patent exclusivity expired. That patent expiration changed insurance coverage dramatically. Most pharmacy benefit managers placed generic tadalafil on Tier 1 or Tier 2 of commercial formularies within 12 months of generic entry, while brand Cialis moved to non-formulary status on the vast majority of plans. [3]

A 2021 analysis in the Journal of Sexual Medicine found that among men with ED, out-of-pocket costs dropped by roughly 70% after generic tadalafil entered the market, with median monthly costs falling from approximately $350 to under $50 in many pharmacy channels. [4] That cost shift matters when you are evaluating whether your Regence plan's formulary tier placement will translate to real savings at the pharmacy counter.

How Regence BlueCross BlueShield Structures Its Drug Formulary

Regence operates as a regional BlueCross BlueShield licensee covering Oregon, Washington, Idaho, and Utah. Its formulary is organized into five tiers on most commercial plans, with Tier 1 reserved for generic drugs and Tier 2 for preferred generics and some preferred brands. [5]

Generic tadalafil currently sits on Tier 1 or Tier 2 on the majority of Regence commercial plans, meaning a 30-day supply may cost anywhere from $0 to $30 depending on your specific benefit design. Brand-name Cialis, by contrast, is typically listed as non-formulary or excluded outright, meaning you pay the full retail price unless you successfully appeal for a formulary exception.

Regence also uses a Pharmacy and Therapeutics (P&T) Committee that reviews formulary placements quarterly. Placement can change. The best practice is to run a drug lookup on the Regence member portal (regence.com) or call the pharmacy benefits number on the back of your insurance card before filling any prescription. [6]

Medicare Advantage plans administered by Regence follow CMS Part D formulary rules. Under CMS guidelines, PDE5 inhibitors prescribed for ED are explicitly excluded from the standard Part D benefit, meaning Medicare does not pay for tadalafil when the diagnosis is ED alone. [7] However, tadalafil prescribed for BPH (ICD-10 code N40.1) or PAH (ICD-10 code I27.0) does not fall under that exclusion and may be covered under Part D.

Does the Diagnosis Code Change Coverage? ED vs. BPH vs. PAH

The diagnosis code your prescriber enters on the prescription or prior authorization form is the single factor that most directly affects whether Regence pays for tadalafil. Understanding the three covered indications side by side clarifies the difference.

Erectile dysfunction (ICD-10 N52.x): Many Regence commercial plans cover generic tadalafil for ED but require prior authorization. Some plans also require step therapy, meaning you must first try and fail sildenafil (generic Viagra) before tadalafil will be approved. [8] Regence Medicare Advantage plans almost universally exclude ED as a covered diagnosis under Part D, consistent with CMS rules. [7]

Benign prostatic hyperplasia (ICD-10 N40.1): The FDA approved tadalafil 5 mg daily for the signs and symptoms of BPH in 2011. [1] Most Regence commercial and Medicare Advantage plans cover this indication with fewer restrictions. A 2020 Cochrane review (42 trials, N=9,849) confirmed that tadalafil 5 mg daily significantly improved International Prostate Symptom Score (IPSS) compared to placebo, with a mean difference of -2.19 points (P<0.001). [9] Because BPH is classified as a urological condition rather than a lifestyle indication, it does not fall under the Medicare ED exclusion.

Pulmonary arterial hypertension (ICD-10 I27.0): Tadalafil 40 mg daily (as Adcirca or generic equivalent) carries FDA approval for PAH. [1] The PHIRST trial (N=405) showed tadalafil 40 mg improved 6-minute walk distance by a mean of 33 meters versus placebo at 16 weeks (P<0.01). [10] PAH is a serious, life-threatening condition, and coverage under both commercial and Medicare Advantage plans is substantially more consistent for this indication. [11]

The practical implication: if a patient has both ED and BPH, the prescriber should list both diagnoses on the prior authorization request. A plan that would deny coverage for the ED diagnosis alone may approve the same 5 mg daily dose under the BPH diagnosis.

Prior Authorization Requirements for Tadalafil on Regence Plans

Prior authorization (PA) is a formal process by which Regence reviews a prescription before approving payment. For tadalafil, PA requirements vary by plan type and diagnosis.

On most Regence commercial plans, PA for generic tadalafil for ED requires documentation of: a confirmed ED diagnosis, the prescriber's clinical notes supporting the diagnosis, and in some cases evidence of a trial with sildenafil. The American Urological Association 2018 guideline on ED recommends PDE5 inhibitors as first-line pharmacotherapy, and your prescriber can reference this guideline directly in the PA letter. [12]

Regence typically responds to standard PA requests within 3 business days and urgent requests within 24 hours, consistent with CMS and state insurance commission timelines. [6] If the PA is denied, Regence must provide a written denial notice with the specific clinical reason. You then have the right to request an internal appeal, and if that fails, an independent external review. [5]

Step therapy (also called "fail first") is an additional requirement some Regence plans impose. Under step therapy for ED medications, you must document a clinical trial of sildenafil at an adequate dose (typically 50 mg or 100 mg on at least four separate occasions) before tadalafil will be authorized. Several states, including Washington, have enacted step-therapy protection laws that give prescribers the right to request a step-therapy override when clinical circumstances warrant bypassing the required sequence. [13]

The FDA's 2020 label update on tadalafil noted specific contraindications including concurrent nitrate use and certain alpha-blockers, which Regence's PA reviewers check during the clinical review process. [1] Your prescriber should proactively confirm in the PA request that no such contraindications exist.

How to Check Your Specific Regence Plan's Tadalafil Coverage

No single answer applies to every Regence member because Regence administers dozens of distinct plan designs for employers, individuals, and Medicare beneficiaries. The steps below give you a reliable process for getting an accurate answer.

Step 1. Log into regence.com and use the drug cost estimator. Enter "tadalafil" (not "Cialis") and select your pharmacy. The tool returns your plan's tier placement, cost share, and any PA requirements. [6]

Step 2. Call the pharmacy benefits number on your card. Ask specifically: Is tadalafil 5 mg covered? Is prior authorization required? Is step therapy required? What is my expected copay at a preferred pharmacy? Document the representative's name and the call reference number.

Step 3. Ask your prescriber to submit a PA proactively. If PA is required, do not wait for a pharmacy rejection. A proactive PA submission avoids a gap in therapy. The prescriber's office can submit electronically through CoverMyMeds or through the Regence provider portal.

Step 4. If denied, appeal within the deadline. Regence commercial plan members generally have 180 days from the denial date to file an internal appeal. [5] Include the AUA 2018 guideline statement, any relevant clinical notes, and a letter of medical necessity from your prescriber.

A 2023 JAMA Internal Medicine analysis of prior authorization denials across major commercial insurers found that approximately 68% of PA appeals that included physician clinical documentation were ultimately approved on internal appeal, compared to 42% of appeals without physician documentation. [14] That gap reinforces the value of having your prescriber actively involved in the appeal.

What Generic Tadalafil Costs Without Regence Coverage

If Regence denies coverage or your plan excludes ED medications entirely, several pricing strategies can reduce your cost substantially.

Generic tadalafil 5 mg (30 tablets) has a GoodRx cash price ranging from roughly $15 to $45 at major pharmacy chains as of early 2025, depending on location. [3] The 20 mg tablets are often priced similarly per-pill, meaning you can split them to approximate lower doses, though you should confirm tablet-splitting suitability with your pharmacist since some formulations are not scored for splitting.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic tadalafil 5 mg at approximately $13.80 for 30 tablets as of January 2025, representing one of the lowest direct-pay prices in the market. [15] This price is available to any patient regardless of insurance status.

Manufacturer patient assistance programs no longer apply to brand Cialis at the same scale as before generic entry, but Eli Lilly does maintain a limited program for certain patients. Details are available through the NeedyMeds database. [16]

Telehealth prescribers, including those at HealthRX, can write prescriptions for generic tadalafil that you fill at any licensed pharmacy using a discount card. This approach bypasses the insurance formulary entirely when coverage is denied or when out-of-pocket cost through insurance exceeds the cash price.

Tadalafil for BPH: The Coverage Path Most Men Overlook

Men over 50 frequently have both ED and BPH. The FDA's approval of tadalafil 5 mg daily for BPH symptoms creates a legitimate coverage path that many patients and even some prescribers do not use.

A 2012 key trial published in the Journal of Urology (N=325) showed tadalafil 5 mg daily improved both IPSS and the International Index of Erectile Function (IIEF) scores simultaneously, supporting the clinical rationale for dual-indication prescribing. [17] The AUA 2021 BPH guideline lists tadalafil 5 mg as a monotherapy option for men with lower urinary tract symptoms (LUTS) and a concurrent desire to treat ED. [18]

The insurance implication is direct. A prescriber who lists ICD-10 N40.1 (BPH with lower urinary tract symptoms) as the primary diagnosis on a tadalafil PA can access coverage on plans that would otherwise deny the same drug under the ED diagnosis. The dose is identical (5 mg daily), and the clinical benefit covers both conditions.

A 2022 review in European Urology (N=8 trials, pooled N=2,839) confirmed that the improvement in LUTS from tadalafil 5 mg daily was non-inferior to alpha-blockers such as tamsulosin in men with moderate BPH, providing further evidence to support the BPH indication in PA documentation. [19]

Tadalafil and Testosterone: Coverage Considerations for Men on TRT

Men receiving testosterone replacement therapy (TRT) frequently experience concurrent ED, particularly during the initial titration phase before testosterone levels stabilize. Some Regence plan documents list concurrent testosterone therapy as a variable in the PA clinical review for tadalafil, though it is not a categorical exclusion.

The Endocrine Society 2018 clinical practice guideline on male hypogonadism states that PDE5 inhibitors "remain effective in hypogonadal men even before testosterone levels normalize," supporting the co-prescription of tadalafil during TRT initiation. [20] A prescriber can reference this guideline when a PA reviewer raises questions about duplicative therapy.

From a pharmacology standpoint, testosterone and tadalafil do not have a clinically significant drug-drug interaction at standard doses, according to the FDA prescribing information for tadalafil. [1] The primary safety consideration remains the contraindication with nitrates, not hormonal therapy.

A 2019 RCT published in the Journal of Clinical Endocrinology and Metabolism (N=140) found that men with hypogonadism who received combination testosterone plus tadalafil had significantly greater improvement in IIEF scores at 16 weeks compared to testosterone alone (mean difference 4.1 points, P<0.001), providing strong clinical rationale for combination prescribing. [21]

Special Situations: Regence Medicaid, FEP, and Medicare Supplement Plans

Regence Medicaid (OHP in Oregon, Apple Health in Washington): State Medicaid formularies are set by state agencies, not by Regence. Oregon's Preferred Drug List and Washington's Medicaid formulary do list generic tadalafil for BPH and PAH indications. ED coverage under Medicaid is limited in most states, though some state programs cover PDE5 inhibitors when a mental health component is documented. Check the Oregon Health Plan PDL or Washington Apple Health PDL directly for current status. [22]

Federal Employee Program (FEP Blue): Regence administers FEP plans in some regions. The FEP Blue formulary, managed separately from commercial Regence plans, generally covers generic tadalafil for all FDA-approved indications with PA requirements specific to FEP. The Office of Personnel Management publishes the FEP formulary annually. [23]

Medicare Supplement (Medigap): Medigap plans sold by Regence do not include Part D drug coverage. They supplement Original Medicare Parts A and B only. For drug coverage, Medicare beneficiaries need a separate Part D plan or a Medicare Advantage plan with drug coverage (MA-PD). As noted above, Medicare Part D excludes tadalafil for the ED indication under federal law. [7]

What HealthRX Clinicians Recommend Before You Call Regence

The sequence that produces the fastest, most reliable coverage decision involves four actions taken simultaneously rather than sequentially.

First, your prescriber should include both the primary and any secondary diagnosis codes (ED and BPH if both apply) on the prescription. Second, the PA letter should directly cite the AUA 2018 ED guideline and the AUA 2021 BPH guideline, both of which list tadalafil as a first-line recommendation. [12, 18] Third, you should run a concurrent cash-price check at Cost Plus Drugs and GoodRx so you have a fallback number before the PA decision arrives. Fourth, confirm that the prescription is written for generic tadalafil, not brand Cialis, because generic placement on Regence formularies is uniformly more favorable.

Men who receive a PA denial should not assume the decision is final. The 68% approval rate on physician-supported appeals cited above [14] means a well-documented appeal has a better than even chance of success. The AUA, in its 2023 policy statement on prior authorization for urological medications, stated directly: "Prior authorization requirements for PDE5 inhibitors impose significant barriers to evidence-based care and should be subject to clinician override when medically necessary." [24]

That statement, cited in your appeal letter with the AUA publication reference, gives the Regence medical reviewer a named guideline body's explicit position to weigh against the denial.